Environment and pharmaceuticals / Environmentially classified pharmaceuticals / D Dermatologicals

Environmentally classified pharmaceuticals

Two substances may have the same risk values but different PBT values, but the risk assessment can also be different even if the PBT values are the same. When assessing a medication's environmental impact, consideration should be given to both environmental risk and environmental hazard since bioaccumulation and persistence are not included in the risk assessment.

The Swedish Association of the Pharmaceutical Industry conducted the environmental risk assessment, beginning in 2005.

How to read the table

Last updated: 2010-06-11

« New search

D Dermatologicals

Substance	Risk	PBT	P	B	T	Volume in DDD	ATC
Antifungals for dermatological use							D01
ketoconazole	moderate	9	3	3	3	3 030 E 4 890 360	J02A B02 D01A C08
miconazole		9	3	3	3	340 276 C 3 156 960	D01A C02 D01A C52
terbinafine		9 N.B.	3 N.B.	3	3	461 412 E 1 060 830	D01A E15 D01B A02
ekonazole	cannot be excl	-	-	-	-	- E 4 875 970	D01A C03 D01A C20 G01A F05
bifonazole	cannot be excl	-	-	-	-	- E 9 345	D01A C10
clotrimazole	cannot be excl	-	-	-	-	- E 581 3704	D01A C01 G01A F02
nystatin	cannot be excl	-	-	-	-	124 702 E 9 285	A07A A02 D01A A01 D07X B02
Emollients and protectives							D02
glycerin	none						D02AX
urea	cannot be excl	6 N.B.	3 N.B.	0	3 N.B.	- E 59 978 305	D02A E01 D07X A01
Antipruritics, including antihistamines, anesthetics, etc							D04
lidocaine	insigni- ficant	3	3	0	0	- C, E 1 142 397	D04A B01 H02A B04 J01D D54 C05A A01 C05A A08 C01B B01 N01B B02 N01B B20 N01B B52 R02A D02 S01J A51
Antipsoriatics							D05
acitretin		9	3	3	3	48 376	D05B B02
Antibiotics and chemotherapeutics for dermatological use							D06
metronidazole	insigni- ficant	4	3	0	1	221 561 E 339 795	D06B X01 A01A B17 G01A F01 J01X D01 P01A B01
retapamulin	cannot be excl	5 N.B.	3	0	2 N.B.	E 145	D06A X13
penciclovir	insigni- ficant	3 N.B.	3	0	0 N.B.	- E 72 320	D06B B06
acyclovir	insigni- ficant	4	3	0	1	E 180 219	J05A B01 D06B B03 S01A D03
fusidic acid	insigni- ficant	5	3	0	2	11 480 E 370 990	D06A X01 D07C A01 D09A A02 J01X C01 S01A A13
mupirocin	cannot be excl	3 N.B.	3 N.B.	0	0 N.B.	- E 20 367	D06A X09
podophyllotoxin	cannot be excl	-	-	-	-	- E 17 383	D06B B04
oxytetracycline		6 N.B.	3 N.B.	0	3 N.B.	9 732 C, E 191 170	D06A A03 D07C A01 J01A A06 S03C A04
gentamicin		6 N.B.	3 N.B.	0	3	8 725 E 3 080	D06A X07 D07C A01 J01G B03
Corticosteroids, dermatological preparations							D07
clobetasone	cannot be excl	4 N.B.	3 N.B.	3	1 N.B.	- E 2 045 181	D07A B01
betamethasone	cannot be excl	9 N.B.	3	3	3 N.B.	2 132 348 E 6 002 715	D07A C01 D07B C01 D05A X52 D07X C01 H02A B01 S02B A07
mometasone	cannot be excl	9 N.B.	3 N.B.	3	3 N.B.	6 536 335 E 5 745 400	D07A C13 R01A D09 R03B A07
hydrocortisone	cannot be excl	1 N.B.	0	0	1 N.B.	370 169 C, E 15 859 355	D07A A02 D07A B02 A07E A02 H02A B09 D01A C20 D07A C16 D07C A01 D07X A01 C05A A01 S01B A02 S03C A04
salicylic acid	insigni- ficant	4 N.B.	3 N.B.	0	1 N.B.	- E 4 570 410	D02A F D11A C08 D07X C01 D07X C03
fusidic acid	insigni- ficant	5	3	0	2	11 480 E 370 990	D06A X01 D07C A01 D09A A02 J01X C01 S01A A13
clobetasol	insigni- ficant	9	3	3	3	- E 1 455 325	D07A D01
triamcinolone	cannot be excl	4 N.B.	3	0	1 N.B.	197 228 E 3 213 285	D07A B09 D07X B02 D07B B03 D01A C20 A01A C01 H02A B08 R01A D11
fluticasone	cannot be exc	6 N.B.	3	0	3 N.B.	1 920 987 E 3 147 10	D07A C17 R01A D08 R03B A05 R01A D12 R03A K06
fluocinolon	cannot be exc	-	-	-	-	- E 27 740	D07A C04
Antiseptics and disinfectants							D08
hydrogen peroxide	cannot be excl	-	-	-	-	- -	D08A X01
Anti-acne preparations							D10
clindamycin	cannot be excl	6 N.B.	3 N.B.	0	3 N.B.	217 368 E 669 318	D10A F01 D10A F51 G01A A10 J01F F01
Other dermatological preparations							D11
finasteride	insigni- ficant	8	3	3	1	2 343 757	D11A X10 G04C B01